Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
561.50    0.50 (0.09%)
Bid:
561.00
Ask:
561.50
Spread: 0.50 (0.089%)
Market Cap: £2.49b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Tate & Lyle to acquire tapioca business

28 Oct 2020 07:00

RNS Number : 3884D
Tate & Lyle PLC
28 October 2020
Β 

Β 

Β 

Tate & Lyle to acquire tapioca business in ThailandΒ 

Agreement to purchase 85% shareholding in Chaodee Modified Starchin support of strategy to grow texturant portfolio

Β 

London, UK, 28 October 2020 - Tate & Lyle PLC ("Tate & Lyle"), a leading global provider of food and beverage ingredients and solutions, announces that it has signed an agreement to acquire an 85% shareholding in Chaodee Modified Starch Co., Ltd. ("CMS"), a well-established tapioca modified food starch manufacturer located in Thailand.

Β 

This investment extends Tate & Lyle's presence in speciality tapioca-based texturants and establishes a dedicated production facility in the main tapioca region of eastern Thailand. The acquisition will enable Tate & Lyle to offer a broader range of tapioca-based solutions to meet customers' needs for better tasting and clean label foods in categories including dairy, bakery, snacks, noodles and soup, sauces and dressings.

Β 

Tate & Lyle will operate CMS in partnership with the former owner. Together with its partner, Tate & Lyle intends to invest in the facility over the next three years to increase significantly capacity for higher functionality starches. The CMS facility will be supplied with substrate by a co-located tapioca starch mill fully owned and operated by Tate & Lyle's partner.

Β 

Nick Hampton, Chief Executive of Tate & Lyle, said: "We are delighted to announce this investment to expand our tapioca offering and grow our texturant portfolio. CMS brings new tapioca capabilities, raw material sourcing expertise and additional production capacity to Tate & Lyle, and expands our presence in the higher growth Asia Pacific region."

Β 

Closing of the transaction will occur when customary approvals have been received.

Β 

End

Β 

Notes to Editor

Β 

1. Thailand is at the centre of tapioca production, with over 90% of tapioca starch output globally1.

2. Tapioca is the most popular and fastest growing texturant source in the Asian diet, and the fastest growing starch in new product formulations2.

3.Β Tapioca has highly desirable functional properties such asΒ a translucentΒ colour, clean taste, and a soft gel-like texture.Β 

__________________________

1. Source: LMC, Commoditia, T&L

2. Source: Mintel GNPD 2015-2019 CAGR

Β 

Β 

For more information contact

Anna Taylor-Elphick, Corporate PR ManagerAnna.taylor-elphick@tateandlyle.comΒ / +44(0)7766361515

Christopher Marsh, VP, Investor RelationsTel: Mobile: +44 (0) 7796 192 688

Β 

About Tate & Lyle:Β Tate & Lyle is a global provider of solutions and ingredients for food, beverage and industrial markets.Tate & Lyle operates through two global divisions, Food & Beverage Solutions and Primary Products, supported by the Innovation and Commercial Development and Global Operations teams. Food & Beverage Solutions is focused on growth by building leading positions globally in the categories of beverages, dairy, and soups, sauces and dressings. Primary Products is focused on delivering steady earnings and generating cash.Food & Beverage Solutions consists of: Texturants, including speciality starches; Sweeteners, including low- and no-calorie sweeteners; and a Health and Wellness portfolio comprising mainly speciality fibres; and Stabilisers and Functional Systems, which are bespoke ingredient blends that ensure foods retain their structure.Primary Products consists of high-volume sweeteners, industrial starches and fermentation products (primarily acidulants). It also sells co-products from the corn milling process as animal nutrition.Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2020, Tate & Lyle sales totalled Β£2.9Β billion. For more information, please visitΒ http://www.tateandlyle.comΒ or follow Tate & Lyle onΒ TwitterΒ orΒ Linkedin.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
ACQQDLFLBBLZFBF
Date   Source Headline
11th Jun 20264:27 pmRNSForm 8.5 (EPT/RI) - Amend - Tate & Lyle PLC
11th Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
11th Jun 20263:00 pmRNSForm 8.3 - TATE & LYLE PLC
11th Jun 20262:32 pmRNSForm 8.3 - Tate & Lyle plc
11th Jun 20262:08 pmRNSForm 8.3 - Tate & Lyle PLC
11th Jun 20262:01 pmRNSForm 8.3 - Tate & Lyle Plc
11th Jun 20261:58 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
11th Jun 20261:48 pmRNSForm 8.3- Tate & Lyle plc
11th Jun 20261:46 pmRNSForm 8.3 - Tate & Lyle plc
11th Jun 20261:25 pmRNSForm 8.3 TATE & LYLE PLC
11th Jun 202611:50 amRNSForm 8.5 (EPT/NON-RI) - TATE & LYLE PLC
11th Jun 202611:48 amRNS20260610_TATE & LYLE_8.5 EPT NON-RI_UK_BOFASE
11th Jun 202611:45 amRNS20260610_TATE & LYLE_8.5 EPT RI_UK_MLI
11th Jun 202611:41 amRNSForm 8.5 (EPT/RI) - Tate & Lyle PLC
11th Jun 202610:47 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
11th Jun 202610:36 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
11th Jun 202610:26 amBUSForm 8.3 - Tate & Lyle plc
11th Jun 202610:11 amRNSForm 8.5 (EPT/RI)
11th Jun 20269:00 amRNSHolding(s) in Company
10th Jun 20266:10 pmRNSForm 8.3 TATE & LYLE PLC Replacement
10th Jun 20263:22 pmRNSForm 8.3 TATE & LYLE PLC
10th Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
10th Jun 20263:05 pmRNSForm 8.3 Tate & Lyle Plc
10th Jun 20263:00 pmRNSForm 8.3 - TATE & LYLE PLC
10th Jun 20262:09 pmRNSForm 8.3 - Tate & Lyle Plc
10th Jun 20262:02 pmRNSForm 8.3 Tate & Lyle plc
10th Jun 20261:53 pmRNSForm 8.3 - Tate & Lyle plc
10th Jun 20261:53 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
10th Jun 202612:07 pmRNSForm 8.3 - Tate & Lyle plc
10th Jun 202611:43 amRNS20260609_TATE & LYLE_8.5 EPT NON-RI_UK_BOFASE
10th Jun 202611:42 amRNSForm 8.3 - Tate & Lyle plc
10th Jun 202611:41 amRNS20260609_TATE & LYLE_8.5 EPT RI_UK_MLI
10th Jun 202611:35 amRNSForm 8.5 - TATE & LYLE PLC
10th Jun 202611:33 amRNSForm 8.5 (EPT/RI) - Tate & Lyle PLC
10th Jun 202611:10 amRNSForm 8.3 - Tate & Lyle plc
10th Jun 202611:05 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
10th Jun 202611:05 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
10th Jun 202610:49 amRNSForm 8.5 (EPT/RI) - Tate & Lyle plc Amend
10th Jun 202610:05 amBUSForm 8.3 - TATE & LYLE PLC
10th Jun 20269:02 amRNSForm 8.5 (EPT/RI)-Amendment
10th Jun 20269:00 amRNSForm 8.5 (EPT/RI)
10th Jun 20269:00 amRNSHolding(s) in Company
9th Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
9th Jun 20263:19 pmRNSForm 8.3 - Tate & Lyle Plc
9th Jun 20262:54 pmRNSForm 8.3 - Tate & Lyle plc
9th Jun 20262:40 pmRNSForm 8.3 TATE & LYLE PLC
9th Jun 20261:50 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
9th Jun 20261:33 pmRNSForm 8.5 (EPT/RI) - Amendment Tate & Lyle PLC
9th Jun 20261:32 pmRNSForm 8.5 (EPT/RI) - Amend - Tate & Lyle PLC
9th Jun 20261:21 pmRNSForm 8.5 - TATE & LYLE PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.